Vorinostat

Drug Profile

Vorinostat

Alternative Names: L-001079038; MK 0683; SAHA; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Zolinza

Latest Information Update: 12 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Columbia University; Memorial Sloan-Kettering Cancer Center
  • Developer Banyu; Columbia University; Dana-Farber Cancer Institute; Fred Hutchinson Cancer Research Center; Groupe Francophone des Myelodysplasies; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Merck & Co; Roswell Park Cancer Institute; Stanford University; University of North Carolina at Chapel Hill; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Hydroxamic acids; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Mesothelioma; Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cutaneous T cell lymphoma
  • Phase II Acute myeloid leukaemia; B cell lymphoma; Breast cancer; Glioma; HIV-1 infections; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Phase I Glioblastoma; Hodgkin's disease
  • Clinical Phase Unknown Brain metastases
  • No development reported Colorectal cancer
  • Discontinued Gynaecological cancer; Mesothelioma; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Sickle cell anaemia

Most Recent Events

  • 01 Aug 2017 Merck initiates enrolment in a phase I/II trial in HIV-1 infections (Combination therapy) in Australia (PO) (NCT03198559)
  • 31 Jul 2017 Discontinued - Phase-II for Sickle cell anaemia (Treatment-experienced) in USA (PO)
  • 21 Jun 2017 Merck terminates a phase II trial due to slow accrual in Sickle cell anaemia (Treatment-experienced) in USA (PO) (NCT01000155)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top